Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
7.41
+0.32 (4.51%)
At close: Jul 24, 2026, 4:00 PM EDT
7.09
-0.32 (-4.32%)
After-hours: Jul 24, 2026, 7:59 PM EDT
Karyopharm Therapeutics Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Karyopharm Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $14.8. The average 1-year stock price forecast is 99.73% higher than the current stock price, while the lowest is $13 (+75.44%) and the highest is $16 (+115.92%).
Price Target: $14.8 (+99.73%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jun 17, 2026.
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 20, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $13 | Buy | Reiterates | $13 | +75.44% | Jun 17, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Hold Reiterates $5 → $7 | Hold | Reiterates | $5 → $7 | -5.53% | May 15, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $8 → $16 | Buy | Reiterates | $8 → $16 | +115.92% | Apr 27, 2026 |
| Robert W. Baird | Robert W. Baird | Buy Maintains $21 → $15 | Buy | Maintains | $21 → $15 | +102.43% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
138.21M
from 146.07M
Decreased by -5.38%
Revenue Next Year
149.00M
from 138.21M
Increased by 7.80%
EPS This Year
-4.95
from -12.22
EPS Next Year
-4.89
from -4.95
EPS and Forward PE are based on non-GAAP adjusted numbers.